Dr. Verschraegen on Combining Immunotherapy Agents in Lung Cancer

Claire Verschraegen, MD
Published: Wednesday, Jun 21, 2017



Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.

Avelumab is different from pembrolizumab (Keytruda) or nivolumab (Opdivo) because it is a PD-L1 monoclonal antibody. Therefore, combining these agents can potentially create a higher benefit for patients.
 


Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.

Avelumab is different from pembrolizumab (Keytruda) or nivolumab (Opdivo) because it is a PD-L1 monoclonal antibody. Therefore, combining these agents can potentially create a higher benefit for patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x